The Supervised Injecting Room Cohort Study (SIRX) aims to provide new evidence of the effectiveness of the Melbourne Medically Supervised Injecting Room (MSIR). The overall SIRX design involves two prospective cohort studies: 1) participants drawn from the existing Melbourne Injecting Drug User Cohort Study through which participants consent to annual behavioural surveys, blood samples and linkage to administrative health records; and 2) a SIRX-Registration Cohort comprising registered MSIR clients who consent to a baseline behavioural survey and administrative data linkage including their SIF use. Causal inference methods will be used to determine the effect of MSIR exposure on health-related outcomes. We will present some preliminary findings from the SIRX Study on the effectiveness of the MSIR in reducing drug-related harms and facilitating other service engagement opportunities.
The Supervised Injecting Room Cohort Study (SIRX)
Ashleigh Stewart | Postdoctoral Researcher, Burnet
Ash is a postdoctoral researcher in the alcohol and other drug research team at the Burnet Institute in Melbourne and leads the implementation of the SIRX study. She primarily works in the fields of injecting drug use and infectious diseases.
Credited Persons
The Harm Reduction stream is sponsored by
